Report this content

Oslo, Norway (13 February 2019) - NattoPharma increased revenues by 52% in the second half of the year and delivered a positive net result in the half year and for the full year 2018. This is coupled with a strong financial position with no interest-bearing debt and an equity ratio of 74,5% as at December 31st, 2018.

“We are very pleased to deliver a strong second half fueled by a record fourth quarter with Product Revenues of approximately NOK 31 million and an EBITDA of 10%. This is the first full year where the Group has a positive net result, demonstrating our ambition of profitable growth. We are especially pleased that we have achieved this already in the first year following the spin-off of the pharma business into Kaydence Pharma AS.

We are also increasing our focus on growing shareholder value. In December we signed an agreement for 2019 with Nordea Markets for Commissioned Research and anticipate the first report to be available in early March. At the same time, we are returning to a quarterly reporting cycle.” Kjetil Ramsøy, CEO NattoPharma.

Financial highlights:

(mnok) H2’18  H2’17  Change  2018  2017  Change 
Product Revenue  54,5  36,0  18,6 (+52%)  101,7  66,4  35,3 (+53%) 
Gross Margin  44,3%  48,8 %  -4,5% 43,1% 47,4%  -4,3% 
Adj. EBITDA  4,2  3,8  0,3  6,7  5,3  1,4 
Net profit  3,2  -0,9  4,1  1,8  -4,1  5,8 

Please find attached the Nattopharma Group 2018 Second Half and Preliminary Full Year Earnings Release.

A presentation will be held via webcast at 10 am CET, Wednesday 13thFebruary 2019, followed by a Q&A session.

Please follow the below link to join the webcast;

For more information, please contact:

Kjetil Ramsøy

CEO, NattoPharma


This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.